Your browser is no longer supported. Please, upgrade your browser.
AIMT Aimmune Therapeutics, Inc. daily Stock Chart
AIMT [NASD]
Aimmune Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.49 Insider Own20.86% Shs Outstand65.45M Perf Week0.15%
Market Cap2.26B Forward P/E- EPS next Y-2.96 Insider Trans438.20% Shs Float49.01M Perf Month0.85%
Income- PEG- EPS next Q-0.96 Inst Own82.85% Short Float8.53% Perf Quarter116.24%
Sales0.58M P/S3925.87 EPS this Y-6.50% Inst Trans- Short Ratio1.94 Perf Half Y116.92%
Book/sh2.75 P/B12.55 EPS next Y30.00% ROA- Target Price31.28 Perf Year40.49%
Cash/sh- P/C- EPS next 5Y34.60% ROE- 52W Range10.09 - 37.00 Perf YTD3.05%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-6.78% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low241.82% ATR0.08
Employees339 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)86.07 Volatility0.19% 0.24%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.45 Prev Close34.49
ShortableNo LT Debt/Eq- EarningsJul 30 AMC Payout- Avg Volume2.15M Price34.49
Recom2.80 SMA200.34% SMA5033.04% SMA20057.03% Volume0 Change0.00%
Jul-13-20Initiated Cowen Outperform $35
May-12-20Reiterated H.C. Wainwright Neutral $30 → $15
Mar-18-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-28-20Reiterated H.C. Wainwright Neutral $33 → $30
Feb-03-20Reiterated Wedbush Outperform $79 → $81
Dec-19-19Initiated H.C. Wainwright Neutral $33
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $30
Jul-12-19Resumed ROTH Capital Buy $45
May-21-19Resumed Credit Suisse Outperform $36 → $30
Dec-13-18Initiated Goldman Neutral $32
May-18-18Resumed Piper Jaffray Overweight
Feb-07-18Initiated RBC Capital Mkts Outperform $55
Dec-21-17Initiated Robert W. Baird Outperform $64
Nov-20-17Initiated ROTH Capital Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Mar-01-16Initiated Wedbush Outperform $42
Nov-17-15Reiterated Piper Jaffray Overweight $35 → $38
Aug-31-15Initiated Piper Jaffray Overweight $35
Aug-31-15Initiated Credit Suisse Outperform $44
Aug-31-15Initiated BofA/Merrill Buy $36
Oct-15-20 07:28PM  
Oct-13-20 01:39AM  
Oct-06-20 07:20AM  
Sep-23-20 03:00PM  
07:00AM  
Sep-22-20 06:50PM  
12:55PM  
Sep-20-20 10:32AM  
Sep-18-20 08:00PM  
Sep-17-20 04:31PM  
Sep-16-20 01:24PM  
Sep-14-20 04:48AM  
01:15AM  
Sep-12-20 11:00AM  
Sep-11-20 08:45PM  
Sep-10-20 08:50PM  
Sep-08-20 10:30AM  
Sep-05-20 11:10AM  
08:30AM  
Sep-04-20 07:37PM  
Sep-03-20 12:52PM  
Sep-01-20 11:17PM  
07:10PM  
01:50PM  
12:30PM  
12:03PM  
11:31AM  
09:12AM  
12:46AM  
Aug-31-20 08:20PM  
06:57PM  
04:52PM  
04:31PM  
04:15PM  
03:39PM  
03:18PM  
12:40PM  
12:09PM  
12:01PM  
11:45AM  
10:08AM  
09:55AM  
08:44AM  
08:35AM  
07:53AM  
07:37AM  
06:55AM  
05:48AM  
04:40AM  
01:47AM  
01:15AM  
Aug-24-20 08:30AM  
Aug-11-20 10:59AM  
Aug-07-20 08:00AM  
Aug-05-20 06:01PM  
08:17AM  
Jul-31-20 03:32AM  
Jul-30-20 06:20PM  
04:05PM  
06:20AM  
Jul-23-20 08:30AM  
Jul-21-20 08:30AM  
Jul-18-20 09:33AM  
Jul-13-20 09:32AM  
Jul-06-20 08:30AM  
Jul-02-20 02:08PM  
12:01PM  
Jun-23-20 11:05AM  
Jun-08-20 11:50AM  
08:00AM  
08:00AM  
Jun-04-20 08:00AM  
Jun-01-20 08:00AM  
May-28-20 07:30AM  
May-19-20 06:18AM  
May-16-20 08:03AM  
May-12-20 08:00AM  
07:16AM  
12:01AM  
May-11-20 05:45PM  
04:05PM  
Apr-30-20 08:00AM  
Apr-08-20 08:00AM  
Apr-07-20 03:33PM  
Mar-22-20 08:06AM  
Mar-21-20 09:15AM  
Mar-17-20 10:40PM  
Mar-16-20 01:12PM  
08:00AM  
Mar-13-20 05:00PM  
Mar-11-20 06:25PM  
Feb-27-20 04:05PM  
07:35AM  
Feb-26-20 08:00AM  
Feb-25-20 08:00AM  
Feb-21-20 09:01AM  
Feb-20-20 05:43PM  
08:30AM  
Feb-19-20 10:13AM  
Feb-13-20 06:45AM  
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. As of October 9, 2020, Aimmune Therapeutics, Inc. operates as a subsidiary of Societe des Produits Nestle S.A.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Societe des Produits Nestle S.10% OwnerOct 13Buy34.5054,117,2871,867,046,40243,435,583Oct 15 07:18 PM
Sheehy Douglas T.See RemarksOct 05Option Exercise12.9530,888400,00085,426Oct 05 09:14 PM
BJERKHOLT ERICChief Financial OfficerOct 05Option Exercise19.445,200101,08849,841Oct 05 09:13 PM
ADELMAN DANIEL C MDChief Medical OfficerOct 02Option Exercise11.4534,932399,97163,807Oct 05 09:20 PM
ENRIGHT PATRICK GDirectorMar 18Buy11.0616,213179,34570,561Mar 19 05:03 PM
ENRIGHT PATRICK GDirectorMar 17Buy11.40100,0001,139,6506,113,134Mar 19 05:03 PM
ENRIGHT PATRICK GDirectorMar 17Buy11.508,787101,05154,348Mar 19 05:03 PM
Oxtoby AndrewChief Commercial OfficerMar 13Buy14.763,00044,26625,015Mar 17 04:51 PM
BJERKHOLT ERICChief Financial OfficerMar 12Buy15.101,00015,10042,967Mar 12 09:13 PM
Dallas Jayson Donald AlexanderPresident and CEOMar 10Buy18.742,66549,934123,283Mar 10 08:48 PM
BJERKHOLT ERICChief Financial OfficerMar 09Buy18.971,00018,97041,967Mar 10 08:47 PM
Societe des Produits Nestle S.10% OwnerFeb 07Buy131.091,525,634200,002,04912,727,113Apr 24 04:59 PM
Sheehy Douglas T.See RemarksJan 16Option Exercise12.954005,18046,068Jan 21 06:17 PM
Sheehy Douglas T.See RemarksJan 16Sale37.0040014,80045,668Jan 21 06:17 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 02Option Exercise19.6320,000392,60041,250Jan 03 08:41 PM
ADELMAN DANIEL C MDChief Medical OfficerJan 02Sale35.0020,000700,03821,250Jan 03 08:41 PM
Sheehy Douglas T.See RemarksDec 26Option Exercise12.9510,000129,50055,668Dec 30 05:14 PM
Sheehy Douglas T.See RemarksDec 26Sale33.0310,000330,32245,668Dec 30 05:14 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 09Option Exercise11.4520,000229,00041,250Dec 11 05:50 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 09Sale30.0420,000600,71621,250Dec 11 05:50 PM